Table 2. Proposed Pathology Workup of Neuroendocrine Prostate Cancer on the Basis of the Study by Haffner et al 72 Morphology Classifier (choose one) IHC Classifier (include the status of each marker) ...

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

The effects of chemotherapy-associated cardiovascular toxicity and alterations in neuroendocrine function ... risk factors for the development of cancer and cognitive problems, including low ...

Fortescue (FMG), Helia (HLI), JB HI-FI (JBH), Judo Capital (JDO), Pro Medicus (PME), Ramelius (RMS), Smartpay (SMP), ...

The US Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.